NOVELMED THERAPEUTICS, INC.

Basic Information

11000 Cedar Avenue, 135
CLEVELAND, OH, 44106-3007

http://www.novelmed.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 190155171
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: 12


  1. Single Therapy for Wet AMD and Geographic Atrophy

    Amount: $548,724.00

    DESCRIPTION (provided by applicant): Approximately 85% of the total age-related macular degeneration (AMD) patients have the Dry form. Geographic atrophy (GA) is the advanced form of Dry AMD and is ca ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Preclinical and Clinical Evaluation of Humanized NM9405

    Amount: $467,832.00

    ABSTRACT NovelMed has developed an anti-properdin antibody (hNM9405) for the treatment of intra and extravascular lysis in paroxysmal nocturnal hemoglobinuria (PNH). The selection of this antibody was ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis

    Amount: $1,451,573.00

    DESCRIPTION (provided by applicant): NovelMed intends to develop a humanized anti-Bb antibody as a prophylactic treatment for inflammatory responses associated with hemodialysis. During this procedur ...

    SBIR Phase II 2014 Department of Health and Human Services
  4. Alternative Pathway Inhibitors for Orphan Indication

    Amount: $889,438.00

    DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. I ...

    SBIR Phase II 2014 Department of Health and Human Services
  5. Set2Read-AK (Alphabet Knowledge)

    Amount: $542,572.00

    DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. I ...

    SBIR Phase I 2013 Department of Health and Human Services
  6. Complement Inhibitors as DMOADs

    Amount: $307,870.00

    DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent amon ...

    SBIR Phase II 2013 Department of Health and Human Services
  7. Complement Inhibitors for Macular Degeneration

    Amount: $1,064,251.00

    DESCRIPTION (provided by applicant): According to the World Health Organization (WHO) global eye disease survey, 14 million people are blind or severely visually impaired due to age-related macular de ...

    SBIR Phase II 2012 Department of Health and Human Services
  8. Complement Inhibitors as DMOADs

    Amount: $294,766.00

    DESCRIPTION (provided by applicant): Complement system play a role in preventing inflammation and joint immobility. Osteoarthritis (OA), an inflammatory disease of the joints, is quite prevalent amon ...

    SBIR Phase I 2012 Department of Health and Human Services
  9. Disease Modifying Biologics for Rheumatoid Arthritis

    Amount: $1,916,919.00

    DESCRIPTION (provided by applicant): Nearly 70 million people in the US suffer from arthritis related conditions[1, 2]. Of these, rheumatoid arthritis (RA) cases constitute approximately 3 million ...

    SBIR Phase II 2011 Department of Health and Human Services
  10. Controlling Inflammation Due to Cardiac Devices

    Amount: $1,352,967.00

    DESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for path ...

    SBIR Phase II 2011 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government